High Court Could Upend Rare Post-Mensing Loss For Generics

Law360, New York (August 3, 2012, 8:49 PM EDT) -- Mutual Pharmaceutical Co. asked the U.S. Supreme Court on Tuesday to reverse the First Circuit's ruling that design defect claims can be leveled against generic-drug companies, a bid that could extinguish the most significant victory plaintiffs have had in suing generics makers since the high court's Mensing decision, experts say.

Mutual filed a petition for writ of certiorari with the high court, arguing the First Circuit erred when it ruled in May that state-law design defect claims against generics makers are not preempted by federal law...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.